Title

Major Lipids and Future Risk of Pneumonia: 20-Year Observation of the Atherosclerosis Risk in Communities (ARIC) Study Cohort

Journal

The American Journal of Medicine, 134(2)

ISSN

0002-9343

Authors

Bae, Sangmee Sharon
Chang, L Cindy
Merkin, Sharon Stein
et al.

Publication Date

2021-02-01

DOI

10.1016/j.amjmed.2020.07.022

Peer reviewed

HHS Public Access

Author manuscript

Am J Med. Author manuscript; available in PMC 2022 February 01.

Published in final edited form as:

Am J Med. 2021 February ; 134(2): 243–251.e2. doi:10.1016/j.amjmed.2020.07.022.

Major Lipids and Future Risk of Pneumonia: 20 year Observation of the Atherosclerosis Risk in Communities (ARIC) Study Cohort

Sangmee Sharon Bae, MD[1], **L. Cindy Chang, MS**[2], **Sharon Stein Merkin, PhD**[3], **David Elashoff, PhD**[4], **Junichi Ishigami, MD**[5], **Kunihiro Matsushita, MD. PhD**[5], **Christina Charles-Schoeman, MD. MS**[1]

[1]University of California Los Angeles, Division of Rheumatology

[2]University of California Los Angeles, Cancer Prevention & Control Res/FSPH & JCCC

[3]University of California Los Angeles, Division of Geriatrics

[4]University of California Los Angeles, Division of General Internal Medicine and Health Services Research

[5]Johns Hopkins Bloomberg School of Public Health and Welch Center for Prevention, Epidemiology, and Clinical Research

Abstract

Background: Circulating lipids have been implicated as important modulators of immune response and altered lipid levels correlate with the severity of infection. However, long-term prognostic implications of lipid levels regarding future infection risk remain unclear. The current project aims to explore whether baseline lipid levels are associated with risk of future serious infection, measured by hospitalization for pneumonia.

Methods: A retrospective analysis was performed in 13,478 participants selected from the Atherosclerosis Risk in Communities (ARIC) study, a large community-based longitudinal cohort in the United States with a median follow up time of >20 years. First incident of hospitalization for pneumonia was identified through hospital discharge records. Cox proportional hazard models were used to assess the association of baseline major lipid levels (total cholesterol, LDL-C, HDL-C, triglycerides) with time to first pneumonia hospitalization.

Results: A total of 1969 (14.61%) participants had a pneumonia hospitalization during a median follow up time of 21.5 years. The hazard ratio (HR) for pneumonia hospitalization was 0.90 (95% CI 0.87–0.92) for every 10 mg/dl increase in baseline HDL-C, and 1.02 (95% CI 1.02–1.03) for every 10mg/dl increase in baseline triglycerides. HDL-C and triglycerides both remained

Corresponding Author: Sangmee Bae, MD, University of California Los Angeles, 1000 Veteran Ave, Rm 32-59, Los Angeles, CA, 90095, Tel: 310-825-2448, Fax: 310-206-8606, sbae@mednet.ucla.edu.

There was no conflict of interest for all authors.

All authors had access to the data and participated in preparation of the manuscript.

significant predictors of pneumonia hospitalization after multivariable adjustment. Such associations were not seen with baseline LDL-C or total cholesterol levels.

Conclusion: Lower baseline HDL-C and higher triglyceride levels were strongly associated with increased risk of long term pneumonia hospitalization in a large longitudinal US cohort.

Keywords

Lipids; Pneumonia; Observational cohort; ARIC cohort

Introduction

Plasma lipid levels have long been studied in the pathogenesis of atherosclerosis and coronary heart disease (1). However, there is increasing evidence that plasma lipids and lipoproteins also play important roles in host immunity (2–4). Patients with bacterial, viral and parasitic infections have altered plasma lipid levels (5–7), and the degree of alteration in lipid levels correlates with the severity of the infection (8, 9). Studies in patients with active infection demonstrate suppressed high-density lipoprotein (HDL) and total cholesterol concentrations, whereas triglyceride levels are increased (10, 11).

HDL in particular is suggested to be an active participant in the innate immune response (4, 12). Prior observational studies suggest a protective association between HDL cholesterol (HDL-C), and risk of future infection (2–7, 12–20). HDL are immunomodulatory particles containing proteins involved in complement activation and the acute inflammatory response (12, 21). However, studies to date report primarily short-term infectious outcomes associated with HDL levels, mostly within a single hospitalization, and long-term prognostic implications for future infection risk remain unclear. Moreover, there is less information available regarding the relationship of other major lipids to the immune response.

In the current study, we employ a large community-based prospective cohort in the United States including over 13,000 participants followed for a median of >20 years to determine whether baseline major lipid levels are associated with risk of future serious infection measured by hospitalization for pneumonia. The significance of this project lies in the identification of lipid profiles as potential targets for prevention of serious infections in the general population.

Methods

Study population

The Atherosclerosis Risk in Communities (ARIC) study is a large community-based prospective cohort study of 15,792 Americans ages 45 to 64 years recruited from 4 different communities in the US (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD) (22). The initial examination was conducted between 1987–1989 (visit 1) and subsequent visits took place in 1990–1992 (visit 2), 1993–1995 (visit 3), 1996–1998 (visit 4), and 2011–2013 (visit 5). The study population for this analysis was selected from visit 2 to ensure that participants with a recent prior event of the primary outcome of pneumonia (detailed subsequently) were excluded. However, there was no information

regarding events prior to visit 1. Of the 14,348 participants with baseline visit (visit 2) data, participants were excluded for lack of additional follow up information (n=4), incidence of pneumonia prior to visit 2 (n=67), race other than black or white given small numbers (n=41), missing plasma lipid data (HDL-C, LDL-C, total cholesterol and triglyceride levels) (n=332) and non-fasting blood collection (n=426). The final population for the primary analysis consisted of 13,478 participants (Figure 1). The IRB at each participating institution approved the ARIC study and all participants provided informed consent before each examination.

Major Lipids

Plasma HDL-C, LDL-C, total cholesterol and triglycerides were measured at a central lipid laboratory at Baylor University. Participants were asked to fast for 12 hours before their visit. Plasma cholesterol and triglyceride were measured by enzymatic methods (23, 24). HDL-C was measured using the Olympus HDL-Cholesterol test (HDL-C), a two-reagent homogenous system that precipitates HDL-C from non-HDL lipoproteins. LDL-C was calculated using Friedewald's formula (25).

Outcome

The outcome of interest was time from baseline (visit 2) to first incident of hospitalization with pneumonia. Pneumonia events among ARIC participants were identified through hospital discharge records obtained through active surveillance of local hospitals using ICD-9-CM codes 480–486. Participants who were never hospitalized for pneumonia were censored when they were lost to follow up, died or administratively censored at the end of the follow-up period, 12/31/2013.

Other covariates of interest

Covariates of interest were assessed at visit 2 except for center and level of education which was collected at visit 1. Smoking status was determined based on self-reported questionnaires. Use of steroids, antineoplastic agents and cholesterol medications including statins were obtained from medication records at visit 2. Hypertension(HTN) was defined as using an antihypertensive drug, systolic blood pressure ≥140$mmHg$ or diastolic blood pressure ≥90$mmHg$. Diabetes(DM) was defined as self-reported physician diagnosis of diabetes, using an antidiabetic drug, fasting glucose level of ≥126mg/dL or random glucose level of ≥200mg/dL. Chronic obstructive pulmonary disease (COPD) was collected from ICD-9-CM codes (490, 491, 492, 494, 496) from hospital discharge records. This information was not available prior to visit 1. eGFR was based on the Chronic Kidney Disease Epidemiology Collaboration serum creatinine and cystatin C equation (26, 27). High-sensitivity C-reactive protein (hs-CRP) was measured at baseline visit using the immunoturbidimetric CRP-Latex(II) hs assay.

Statistical analysis

Baseline characteristics were compared by baseline major lipid quartiles using $\chi 2$ tests for categorical and Kruskal Wallis tests for continuous variables. We used Cox proportional hazard analysis to test the association between baseline lipid levels and time to first

pneumonia hospitalization. Models were adjusted for demographics, education, smoking, steroids, antineoplastic agents, eGFR and comorbidities (presence of HTN or DM or COPD). Observed incidence of pneumonia hospitalization over time was assessed by baseline lipid quartiles to address potential non-linear effects. Log-rank test was applied to compare survival between quartiles. Sensitivity analysis was performed in participants with baseline hs-CRP values available (N=12,601), and base-10 logarithm transformation was applied when included in models to fit log linearity. Interactions were assessed using two-factor interaction terms between lipid variables that were significantly associated with the primary outcome. Model discrimination was assessed using C-statistic (28). Assumptions were checked and satisfied. All reported p-values are based on two sided tests, and <0.05 was considered statistically significant. Data was processed and analyzed using SAS version 9.4 (SAS institute, Cary, NC).

Results

Pneumonia hospitalization risk and Baseline Characteristics

The median age of participants was 57 years; 56% were female, and 76% were white. Participants were followed for a median of 21.5 (IQR of 15.8–22.6) years, and 1969 (14.6%) participants experienced incident pneumonia hospitalization during follow-up. Comparison of demographics, lifestyle factors, comorbidities between participants by baseline HDL-C (Table 1) and triglyceride quartiles(Table 2) showed that patients in the lower HDL-C quartiles and higher triglyceride quartiles had higher BMI, hs-CRP, higher rates of smoking and comorbidities (HTN, DM, COPD).

Pneumonia hospitalization risk and Baseline Lipid levels

Participants who had pneumonia hospitalizations had lower baseline HDL-C levels and higher triglyceride levels compared with those who did not have pneumonia events (Table S1). When divided into quartiles, subjects with the lowest baseline HDL-C (HDL-C 1st quartile, Q1) had significantly more pneumonia hospitalization events(n=572, 17%) compared to subjects with higher baseline HDL-C levels (Q2: 565(15%); Q3: 415(14%); Q4: 417(12%), $p<0.01$, Figure 2–a). For triglyceride quartiles, there was a graded increased risk of pneumonia the higher the baseline triglyceride quartile (Q1: 432(13%); Q2: 461(14%); Q3: 503(15%); Q4: 573(17%), $p<0.01$, Figure 2–d). Such trends were not seen in the LDL-C quartiles or the total cholesterol quartiles (Figure 2–b, c).

In Cox proportional hazard models, hazard ratio (HR) of pneumonia hospitalization was 0.90 (95% CI 0.87–0.92) for every 10 mg/dl increase in baseline HDL-C. Triglyceride also showed a significant association with pneumonia hospitalization, with HR of 1.02 (95% CI 1.02–1.03) for every 10 mg/dl increase in baseline triglyceride levels (Table 3). LDL-C and total cholesterol were not associated with risk of pneumonia hospitalizations.

In multivariable analysis adjusted for demographics (age, gender, race, center), smoking, education level, medications, renal function and comorbidities, baseline low HDL-C and high triglyceride remained a significant predictor of the risk of pneumonia hospitalization (Table 3, Supplementary Table 2). The graded association between pneumonia with HDL-C

and triglyceride was observed across the entire range of HDL-C and triglycerides (Supplementary Figure).

Elevated levels of hs-CRP is a widely used biomarker of acute inflammation, and has been demonstrated to be independently associated with higher risk of future infection (29). In a sensitivity analysis restricting to participants with baseline hs-CRP values available (N=12,601), triglycerides maintained significant HRs in all models (data not shown).

Pneumonia hospitalization risk according to HDL-C by triglyceride quartiles

As HDL-C and triglycerides both remained strong predictors of the primary outcome, we tested whether there was an interaction between HDL and triglyceride and found it to be non-significant. Nonetheless, we examined the risk of pneumonia hospitalizations according to HDL-C quartiles stratified by each triglyceride quartile, as the function of HDL particles can be altered by their triglyceride content. The association between HDL-C concentration and risk of pneumonia hospitalizations remained strong regardless of triglyceride quartiles (Figure 3). Participants in HDL-C Q4 had the lowest incidence of pneumonia hospitalizations within each triglyceride quartile. In triglyceride quartile 2 and 3, incidence of pneumonia hospitalization increased sequentially from HDL Q4 to Q1. Within triglyceride Q1-Q3, subjects in lower HDL-C quartiles trended towards higher adjusted HR for pneumonia. Interestingly, most participants in the highest triglyceride quartile (triglyceride Q4) had significantly increased risk of pneumonia hospitalizations regardless of HDL-C.

Discussion

In the current study, we demonstrate that differences in certain baseline lipid levels are associated with a higher risk of future pneumonia hospitalizations in a large prospective cohort of 4 US communities. Participants with low HDL-C or high triglyceride levels at baseline had a significantly increased risk of future pneumonia hospitalizations over a median follow up time of >20 years, independent of other known risk factors such as age, smoking status, antineoplastic medication use, steroid use, renal dysfunction or presence of comorbidities. Such associations were not seen for LDL-C or total cholesterol.

Our results support the hypothesis that there is a link between lipid metabolism and the immune system. Studies have demonstrated decreased lipoprotein cholesterol levels in patients with critical illness, severe sepsis and other acute infections. (5, 6, 10, 11, 30, 31). HDL in particular has been suggested to play an important role as a part of the innate immune response using rapid induction of an oxidative state as a way of combating pathogens (32, 33). HDL also demonstrates anti-inflammatory, antioxidant properties by affecting the expression of local adhesion molecules and cytokine secretion by immune cells (33, 34). Decreased HDL-C, has been shown to have prognostic implications in short term studies of hospitalized patients. Patients with lower baseline HDL-C on admission had increased rates of infectious complications, intensive care unit (ICU) admissions and mortality during hospitalization (6, 15, 31, 33, 35–37). An inverse correlation between HDL-C levels at admission and plasma acute phase reactants such as CRP has been reported in a retrospective study of 107 patients hospitalized with community-acquired pneumonia at a

University hospital in Spain (37), and was also observed in our current study. In the former retrospective study, low HDL baseline levels at hospital admission associated with development of septic shock, ICU admission, and the presence of a pleural effusion complicating the pneumonia.

Fewer studies have looked at the association between serum lipids and long-term risk of developing infections. A recent study of two large Danish cohorts including 97,166 individuals from the Copenhagen General Population(CGP) Study and 9,387 individuals from the Copenhagen City Heart(CCH) Study demonstrated a U-shaped association between HDL-C levels and risk of hospitalization from infection, over a median follow up times of 6 and 20 years respectively (20). In the CGP cohort, the HR for any infection was 1.75 (95% CI 1.31–2.34) in subjects with the lowest HDL-C (<31 mg/dL) and 1.43 (1.16–1.76) in subjects with the highest HDL-C (≥100 mg/dL) compared to the referent group (HDL-C=85–95 mg/dL). Among different types of infections, gastroenteritis and bacterial pneumonia had the highest risk estimates. Similar associations between low and high HDL-C levels and risk of infectious disease were confirmed in the CCH cohort. This data supports the hypothesis that circulating lipids may play an important long-term role in the body's defense against infectious pathogens. However, certain points should be considered in the interpretation of these findings. Participants in the Danish study were all white individuals of Danish descent, whereas the ARIC cohort had a broader ethnic population including 24% blacks. Also, participants in ARIC had lower median HDL-C (47mg/dL in ARIC vs. 54–62 mg/dL in the CGP cohort), higher proportions of obesity (BMI ≥30; 28.4% in ARIC vs. 16% in the CGP cohort) and diabetes (13.5% in ARIC vs 4% in the CGP cohort) which is reflective of the higher prevalence of metabolic syndrome in America compared to Europe. Also, ascertainment of the primary outcome in ARIC was through active surveillance of the cohort rather than from a separate registry as was done in the Danish study, which further increases its reliability. Our study did not demonstrate the U-shaped association between HDL-C levels and risk of infections which may partially be explained by the small number of patients in ARIC with extremely high HDL-C levels (above 100 mg/dL). Nonetheless, our findings show HDL-C levels are strongly associated with long-term risk of serious infections while LDL-C and total cholesterol levels are not, which is in agreement with the Danish study.

The current work is the first large study in the general population to demonstrate a strong, significant association between higher baseline triglyceride levels and risk of future infection. Patients with elevated triglycerides are at increased risk for cardiovascular mortality (38) and lowering triglycerides leads to a significant reduction in ischemic events (39). However, the effect of triglyceride levels in regard to inflammatory states is less consistent between studies. While some studies show increased triglyceride levels during acute infections (10, 11), other studies including the Danish study have demonstrated no significant association between triglyceride levels and infectious outcomes (6, 20). Most studies are limited in sample size and follow up time. In the Danish study, triglyceride levels were not associated with infectious risks after multivariate adjustment. Our study demonstrated that higher triglycerides remained strongly associated with increased risk of hospitalization for pneumonia after multivariate adjustment. The current study is also strengthened by our ability to rigorously measure the lipid profiles in fasting condition

excluding the possibility of postprandial effects on triglycerides, which was not done in other studies.

Studies have previously shown that the composition of HDL-C is modified to have higher triglyceride content in patients with hypertriglyceridemia as well as in acute inflammatory states (40). Such triglyceride-enriched HDL-C particles appear to be aberrant in their functional properties including their anti-oxidative function (41). Here we evaluated the risk of pneumonia according to HDL-C quartiles within each triglyceride quartile and found that high HDL-C was consistently associated with lower risk of pneumonia in all triglyceride quartiles. This supports the *a priori* hypothesis that HDL-C plays a protective role in the host immune response. Interestingly, participants in the highest triglyceride quartile had significantly increased risk of pneumonia regardless of HDL-C quartile. We postulate that subjects in the highest triglyceride quartile may represent subjects with altered HDL function due to triglyceride enrichment which may be more influential than the HDL level itself. Further studies are needed to gain a better understanding of how triglyceride enriched lipoproteins may modulate the host immune response.

While current lipid modifying therapies are largely used to prevent cardiovascular events, the current findings suggest they may also generate additional benefit in preventing future infections. Although our findings cannot confirm that initiating agents to modify HDL-C or triglyceride levels lower the risk of future infections, they encourage maintaining healthy lipid profiles for reasons beyond cardiovascular prevention. In addition, when prescribing non-lipid medications that modify lipid levels physicians may consider medications that increase HDL-C if possible, particularly in patients with high risk of future infections. Absolute benefits of increasing HDL-C are likely to be greater in patients without extremely high triglyceride levels.

Our study has several limitations. First, although we excluded patients with known pneumonia hospitalizations, initial cohort enrollment was not designed to assess infectious outcomes and we do not have information about pneumonia events before the start of the ARIC study; thus the association between baseline lipid levels and pneumonia hospitalizations cannot be established as causal. Second, use of a population-based cohort allowed us to study a large number of participants over a long follow up period, but there were constraints in age and ethnicity. For generalizability of our findings, future studies should be considered in more diverse populations. Lastly, we censored patients after their first episode of pneumonia hospitalization; assessment of repeated events or competing risks of other illnesses/death may have an effect on risk estimates.

In conclusion, after analyzing 13,478 participants in a longitudinal prospective US cohort, we found that lower HDL-C and higher triglyceride levels at baseline are associated with a significantly increased risk of future pneumonia. Our study provides evidence that alterations in certain lipids may play important roles in modulating the host's immune response. Future studies are needed to assess the efficacy of improving serum lipid levels by lifestyle and pharmacologic interventions in modifying future infection risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This project was supported by the UCLA Older American Independence Center (NIH P30 AG028748) and NIH National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881. The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the NHLBI, NIH, Department of Health and Human Services (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). The authors thank the staff and participants of the ARIC study for their important contributions.

Funding source: Dr. Charles-Schoeman received support from the NHLBI (R01HL123064). This project was supported in part by the UCLA Older American Independence Center (NIH P30 AG028748) and NIH National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881. The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the NHLBI, NIH, Department of Health and Human Services (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). Funding source had no participation in study design; in the collection, analysis, and interpretation of data; in writing the report; or in the decision to submit the article for publication.

Reference

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52. [PubMed: 15364185]
2. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169–96. [PubMed: 15102878]
3. Han R. Plasma lipoproteins are important components of the immune system. Microbiol Immunol. 2010;54(4):246–53. [PubMed: 20377753]
4. Murphy AJ, Chin-Dusting JPF, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins,. Current Medicinal Chemistry. 2009;16(6):667–75. [PubMed: 19199930]
5. Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med. 1969;281(20):1081–6. [PubMed: 5824173]
6. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med. 1996;24(4):584–9. [PubMed: 8612407]
7. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31(5):1359–66. [PubMed: 12771603]
8. Deniz O, Tozkoparan E, Yaman H, Cakir E, Gumus S, Ozcan O, et al. Serum HDL-C levels, log (TG/HDL-C) values and serum total cholesterol/HDL-C ratios significantly correlate with radiological extent of disease in patients with community-acquired pneumonia. Clin Biochem. 2006;39(3):287–92. [PubMed: 16487950]
9. Deniz O, Gumus S, Yaman H, Ciftci F, Ors F, Cakir E, et al. Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis. Clin Biochem. 2007;40(3–4):162–6. [PubMed: 17217941]
10. Rodriguez Reguero JJ, Iglesias Cubero G, Vazquez M, Folgueras I, Braga S, Bustillo E, et al. Variation in plasma lipid and lipoprotein concentrations in community-acquired pneumonia a six-month prospective study. Eur J Clin Chem Clin Biochem. 1996;34(3):245–9. [PubMed: 8721412]
11. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 1988;37(9):859–65. [PubMed: 3419323]

12. Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2012;220(1):11–21. [PubMed: 21783193]
13. Barcia AM, Harris HW. Triglyceride-rich lipoproteins as agents of innate immunity. Clin Infect Dis. 2005;41 Suppl 7:S498–503. [PubMed: 16237653]
14. Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Gluck T, et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med. 2009;35(11):1877–85. [PubMed: 19669126]
15. Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med. 2005;33(8):1688–93. [PubMed: 16096442]
16. Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK, et al. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest. 2010;40(4):330–8. [PubMed: 20486994]
17. Gruber M, Christ-Crain M, Stolz D, Keller U, Muller C, Bingisser R, et al. Prognostic impact of plasma lipids in patients with lower respiratory tract infections - an observational study. Swiss Med Wkly. 2009;139(11–12):166–72. [PubMed: 19330560]
18. Rodriguez-Sanz A, Fuentes B, Martinez-Sanchez P, Prefasi D, Martinez-Martinez M, Correas E, et al. High-density lipoprotein: a novel marker for risk of in-hospital infection in acute ischemic stroke patients? Cerebrovasc Dis. 2013;35(3):291–7. [PubMed: 23595024]
19. Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux A, et al. Low HDL levels and the risk of death, sepsis and malignancy. Clin Res Cardiol. 2008;97(4):227–33. [PubMed: 18060375]
20. Madsen CM, Varbo A, Tybjaerg-Hansen A, Frikke-Schmidt R, Nordestgaard BG. U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies. Eur Heart J. 2018;39(14):1181–90. [PubMed: 29228167]
21. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117(3):746–56. [PubMed: 17332893]
22. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(April):687–702. [PubMed: 2646917]
23. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–5. [PubMed: 4818200]
24. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19(5):476–82. [PubMed: 4703655]
25. Tietz NW. Textbook of Clinical Chemistry, WB Saunders. 1986:888.
26. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9. [PubMed: 22762315]
27. Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and Risk for Hospitalization With Infection: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2017;69(6):752–61. [PubMed: 27884474]
28. Liu L, Forman S, Barton B. Fitting Cox Model Using PROC PHREG and Beyond in SAS. SAS Global Forum 2009 2009(236).
29. Wang HE, Shapiro NI, Safford MM, Griffin R, Judd S, Rodgers JB, et al. High-sensitivity C-reactive protein and risk of sepsis. PLoS One. 2013;8(7):e69232.
30. Chien YF, Chen CY, Hsu CL, Chen KY, Yu CJ. Decreased serum level of lipoprotein cholesterol is a poor prognostic factor for patients with severe community-acquired pneumonia that required intensive care unit admission. J Crit Care. 2015;30(3):506–10. [PubMed: 25702844]
31. Giovannini I, Boldrini G, Chiarla C, Giuliante F, Vellone M, Nuzzo G. Pathophysiologic correlates of hypocholesterolemia in critically ill surgical patients. Intensive Care Med. 1999;25(7):748–51. [PubMed: 10470581]
32. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med. 2005;15(4):158–61. [PubMed: 16099381]
33. Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. Cardiovasc Res. 2014;103(3):372–83. [PubMed: 24935428]

34. Sviridov D, Remaley AT. High-density lipoprotein mimetics: promises and challenges. Biochem J. 2015;472(3):249–59. [PubMed: 26613945]

35. Gui D, Spada PL, De Gaetano A, Pacelli F. Hypocholesterolemia and risk of death in the critically ill surgical patient. Intensive Care Med. 1996;22(8):790–4. [PubMed: 8880248]

36. Peng YS, Chen YC, Tian YC, Yang CW, Lien JM, Fang JT, et al. Serum levels of apolipoprotein A-I and high-density lipoprotein can predict organ failure in acute pancreatitis. Crit Care. 2015;19:88. [PubMed: 25851781]

37. Saballs M, Parra S, Sahun P, Pelleja J, Feliu M, Vasco C, et al. HDL-c levels predict the presence of pleural effusion and the clinical outcome of community-acquired pneumonia. Springerplus. 2016;5(1):1491. [PubMed: 27652064]

38. Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, et al. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes. 2016;9(2):100–8. [PubMed: 26957517]

39. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. [PubMed: 30415628]

40. Skeggs JW, Morton RE. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J Lipid Res. 2002;43(8):1264–74. [PubMed: 12177170]

41. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, et al. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J. 2011;75(7):1533–8. [PubMed: 21628835]

Highlights

- Lipids are implicated as important modulators of immune response
- Longitudinal observation cohort study to asses risk of pneumonia
- Lower HDL-C and higher triglyceride associated with higher risk of future pneumonia
- Altered lipids have long term implications in future infections



Figure 1.
Flowchart of participants included



Figure 2.
Pneumonia hospitalization cumulative hazard by major lipid quartiles



Figure 3.

Risk of pneumonia events according to HDL by triglyceride quartiles

Referent group is triglyceride Quartile 1-HDL Quartile 4

Adjusted for covariate set 1: age, gender, race, center

Table 1.

Baseline characteristics by HDL quartiles

Characteristics	HDL quartiles				P-value*
	Q1 (<38mg/dL)	Q2 (38–46.9mg/dL)	Q3 (47–58.9mg/dL)	Q4 (≥59mg/dL)	
Age, Median (IQR)	57(52–62)	57(52–62)	56(52–62)	56(52–61)	<0.01
Race					
White	2833(84.2)	2847(77.8)	2155(71.5)	2431(70.7)	<0.01
Gender					
Female	912(27.1)	1720(47.0)	2042(67.8)	2819(81.9)	<0.01
Center					
Forsyth County NC	956(28.4)	939(25.7)	699(23.2)	864(25.1)	<0.01
Jackson, MS	463(13.8)	708(19.4)	758(25.2)	894(26.0)	
Minneapolis, MN	861(25.6)	990(27.1)	796(26.4)	997(29.0)	
Washington County, MD	1084(32.2)	1022(27.9)	761(25.3)	686(19.9)	
Smoking status					
Current cigarette smoker	916(27.2)	832(22.8)	599(19.9)	621(18.1)	<0.01
Former cigarette smoker	1437(42.8)	1444(39.5)	1090(36.2)	1144(33.3)	
Never smoked cigarettes	1003(29.9)	1376(37.7)	1323(43.9)	1673(48.7)	
BMI (kg/m^2), Median (IQR)	28.4(25.8–31.5)	27.5(24.8–31.0)	27.0(24.0–30.8)	25.2(22.5–28.6)	<0.01
Education					
12 years or more	2578(76.8)	2884(78.9)	2341(77.8)	2794(81.3)	<0.01
Medications					
Cholesterol lowering medication including Statins	271(8.1)	261(7.2)	178(5.9)	152(4.4)	<0.01
Steroids	19(0.6)	46(1.3)	38(1.3)	79(2.3)	<0.01
Antineoplastic agents	17(0.5)	22(0.6)	14(0.5)	25(0.7)	0.51
Comorbidities					
Hypertension	1334(39.8)	1325(36.3)	1042(34.7)	1045(30.5)	<0.01
Diabetes	681(20.3)	564(15.5)	358(11.9)	216(6.3)	<0.01
COPD	3(0.1)	4(0.1)	0(0)	3(0.1)	0.4
Patients with comorbidities $^{\tau}$	1633(48.7)	1564(42.9)	1182(39.3)	1139(33.3)	<0.01
eGFR (mL/min/1.73m2), Median (IQR)	95.5(85.5–102.9)	96.6(88.0–104.6)	98.5(89.8–107.4)	99.6(91.4–107.8)	<0.01
Hs-CRP (mg/dL))$^{\xi}$, Median (IQR)	2.52(1.28–5.06)	2.27(1.13–4.91)	2.22(1.04–4.88)	1.80(0.83–4.18)	<0.01

*Chi-square tests were used for categorical variables and Wilcoxon rank-sum tests were applied for continuous variables.

$^{\xi}$hsCRP collected in total N=12,601 (pneumonia event yes N=1805, no N=10796)

τPatients with comorbidities include patients with at least 1 comorbid condition

Table 2.

Baseline characteristics by Triglyceride quartiles

Characteristics	Triglyceride quartiles				P-value*
	Q1 (<80.2mg/dL)	Q2 (80.2–110.8mg/dL)	Q3 (110.9–157.4mg/dL)	Q4 (157.5mg/dL)	
Age, Median (IQR)	56(51–61)	57(52–62)	57(53–62)	57(53–62)	<0.01
Race					
White	2250(66.3)	2461(73.4)	2673(78.8)	2882(86.3)	<0.01
Gender					
Female	2012(59.3)	1940(57.9)	1875(55.3)	1666(49.9)	<0.01
Center					
Forsyth County NC	789(23.2)	867(25.9)	896(26.4)	906(27.1)	<0.01
Jackson, MS	1003(29.5)	778(23.2)	632(18.6)	410(12.3)	
Minneapolis, MN	915(27.0)	884(26.4)	915(27.0)	930(27.8)	
Washington County, MD	688(20.3)	822(24.5)	949(28.0)	1094(32.8)	
Smoking status					
Current cigarette smoker	673(19.9)	751(22.5)	777(22.9)	767(23.0)	<0.01
Former cigarette smoker	1215(35.8)	1242(37.1)	1287(38.0)	1371(41.1)	
Never smoked cigarettes	1503(44.3)	1351(40.4)	1325(39.1)	1196(35.9)	
BMI (kg/m^2), Median (IQR)	25.5(22.9–28.7)	26.7(23.8–30.2)	27.5(24.9–31.0)	28.6(25.8–31.9)	<0.01
Education					
12 years or more	2719(80.2)	2589(77.4)	2658(78.6)	2631(78.8)	0.05
Medications					
Cholesterol lowering medication including Statins	139(4.1)	158(4.7)	231(6.8)	334(10.0)	<0.01
Steroids	43(1.3)	51(1.5)	43(1.3)	45(1.4)	0.78
Antineoplastic agents	17(0.5)	17(0.5)	22(0.7)	22(0.7)	0.73
Comorbidities					
Hypertension	950(28.1)	1089(32.6)	1243(36.7)	1464(44.0)	<0.01
Diabetes	229(6.8)	333(10.0)	480(14.2)	777(23.3)	<0.01
COPD	1(0.03)	4(0.12)	2(0.06)	3(0.09)	0.56
Patients with comorbidities $^{\tau}$	1055(31.2)	1239(37.2)	1455(43.0)	1769(53.2)	<0.01
eGFR (mL/min/1.73m2), Median (IQR)	99.8(91.4–108.9)	97.8(88.8–105.8)	96.3(87.3–104.3)	95.8(86.6–103.3)	<0.01
Hs-CRP (mg/dL))$^{\xi}$, Median (IQR)	1.54(0.74–3.51)	2.04(0.98–4.35)	2.51(1.22–5.21)	2.82(1.45–5.75)	<0.01

*Chi-square tests were used for categorical variables and Wilcoxon rank-sum tests were applied for continuous variables.

$^{\xi}$hsCRP collected in total N=12,601 (pneumonia event yes N=1805, no N=10796)

τPatients with comorbidities include patients with at least 1 comorbid condition

Table 3

Hazard ratios of pneumonia hospitalization

	Covariate set	HR (95% CI)
HDL-C (Unit: 10 mg/dL)	**Unadjusted**	0.90 (0.87, 0.92) **
	Covariate set 1	0.93 (0.90, 0.96) **
	Covariate set 2	0.97 (0.94, 1.00) *
LDL-C (Unit: 10 mg/dL)	**Unadjusted**	1.01 (1.00, 1.02)
	Covariate set 1	1.00 (0.99, 1.01)
	Covariate set 2	1.00 (0.99, 1.01)
Total cholesterol (Unit: 10 mg/dL)	**Unadjusted**	1.00 (0.99, 1.02)
	Covariate set 1	1.00 (0.99, 1.01)
	Covariate set 2	1.00 (0.99, 1.01)
Triglyceride (Unit: 10 mg/dL)	**Unadjusted**	1.02 (1.02,1.03) **
	Covariate set 1	1.02 (1.01, 1.03) **
	Covariate set 2	1.01 (1.00, 1.02) *

* p<0.05

** p<0.001

Reported HR is per 10mg/dL change in lipid level.

Covariate set 1: adjusted for demographics including age, race, gender, center

Covariate set 2: adjusted for Covariate set 1 and education, smoking, steroid, antineoplastic agents, eGFR, comorbidities (presence of diabetes or hypertension or COPD)